Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCT with Matched Unrelated Donors in Hematologic Malignancies
NCT00054327Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Nov 2000
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide, cytarabine, busulfan and etoposide in leukemia, lymphoma, myelodysplastic syndrome (MDS) and 1 more (6 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Rates of Durable Engraftment at 42 days. Started Nov 2000; status: completed.
02
Drugs
cyclophosphamidecytarabinebusulfanetoposide
03
Conditions
leukemialymphomamyelodysplastic syndrome (MDS)myeloproliferative neoplasm (MPN)
Beyond the preview
Go deeper on NCT00054327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054327.